Misonix (NASDAQ:MSON) announced its earnings results on Thursday. The medical equipment provider reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34, Fidelity Earnings reports. Misonix had a negative return on equity of 25.99% and a negative net margin of 19.01%. The business had revenue of $11.15 million during the quarter.
Shares of NASDAQ MSON traded up $2.87 during mid-day trading on Friday, hitting $19.62. 103,600 shares of the company traded hands, compared to its average volume of 43,956. Misonix has a 1 year low of $13.87 and a 1 year high of $27.54. The business has a 50 day moving average of $18.09 and a two-hundred day moving average of $20.76.
MSON has been the subject of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 target price (up from $24.00) on shares of Misonix in a report on Thursday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $27.00 target price on shares of Misonix in a report on Thursday, August 15th. Finally, ValuEngine downgraded Misonix from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Misonix currently has an average rating of “Buy” and an average target price of $28.50.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: Resistance Level
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.